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Introductory Chapter: Rare 
Diseases - Ending the Diagnostic 




Rare disease is any disease or condition that affects a small percentage of the 
population. For instance, in the United States, a rare disease is defined as a condi-
tion that affects fewer than 200 000 people, whereas in Europe, a disease is consid-
ered rare when it affects less than 1 in 2000 people within the general population. 
Thus, a rare disease is a health condition that affects small number of people com-
pared with other prevalent diseases in the general population [1]. However, specific 
issues are raised with respect to their rarity. This implies that a disease can be rare in 
one region, but common in another region, for example, thalassemias, a heteroge-
neous group of genetic disorders of blood that reduces the production of functional 
hemoglobin (the protein in red blood cells that carries oxygen). Thalassemia is rare 
in Northern Europe but more common in the Mediterranean region as well in South 
and South-East Asia.
Since rare diseases are numerous, heterogeneous in nature, and geographically 
disparate, rare diseases are an emerging global public health priority. Until now, 
between 6000 to 8000 distinct rare diseases have been discovered, and new rare 
diseases are reported constantly in the medical literature [1]. In general, rare diseases 
affect more than 25 million people in the United States alone, 30 million people in 
the European Union, and more than 400 million people Worldwide. Generally, 72% 
of rare diseases are genetic origin and almost 70% of rare diseases are exclusively 
of pediatric onset, according to the Orphanet, a publicly available epidemiological 
database that contains information on 6172 unique rare diseases [2].
When of genetic origin, rare disease can be inherited, with several other 
affected family members, following different modes of inheritance; or they may 
arise in sporadic, with no other affected family members; or may occur due to 
de novo chance mutations in candidate genes. For several rare conditions, on the 
one hand, the signs of disease could be observed prior to or during delivery or in 
childhood, as in the case of achondroplasia, osteogenesis imperfecta (OI, brittle 
bone disease), spinal muscular atrophy (SMA), or Rett syndrome (RTT). On the 
other hand, the initial presentation of rare diseases can be observed only during 
adulthood, as in the case of Huntington’s disease (HD, Huntington’s Chorea), 
amyotrophic lateral sclerosis (ALS, Lou Gehrig’s disease), Crohn’s disease (IBD, 
inflammatory bowel disease), or Charcot–Marie–Tooth Disease (CMT, hereditary 
motor and sensory neuropathies). While in essence all genetic diseases are rare 
diseases, not all rare diseases are of genetic diseases. This indicates that there are 
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also rare forms of non-genetic rare diseases including certain types of autoim-
mune diseases and rare cancers, such as systemic lupus erythematosus (SLE) and 
Kaposi sarcoma (KS), respectively. As well as maladies caused by infectious or 
toxic agents.
2. Evolving challenges and next frontiers
Rare diseases are often complex, may involve chronic illness, disability, and often 
premature death. As well they are characterized by a remarkably diverse set of symp-
toms; and relatively common symptoms can mask the underlying rare diseases, leading 
to frequent misdiagnosis. Symptoms can vary not only from one rare disease to another 
rare disease but also from one patient to another patient suffering from the same rare 
disease; even occasionally, the symptoms can differ from a family member to a relative 
with the same genetic change. At present, a few hundred rare diseases have any avail-
able treatments, in most cases, neither a cure nor highly effective treatment is available.
Due to their rarity, patients suffering from rare disease often face certain com-
mon problems and challenges, such as delay in getting a correct diagnosis; lack of 
information and/or scientific knowledge on their own disease; lack of appropriate 
healthcare; as well as difficulties and inequities in accessing treatment and care. The 
other lingering obstacles in developing treatment, such as safe and effective drugs and 
biological products for rare diseases, are due to difficulties in diagnosis; small num-
bers and geographically dispersed patients and scientific experts; a lack of data from 
natural history studies; missing biomarkers to support the clinical development of 
new therapeutics; as well a perception of high economic risk in developing drugs that 
would serve either a relatively small population with a rare disease or a larger popula-
tion suffering from a common disease that primarily affects developing countries.
Understandably, nearly all rare disease patients, including their families, have 
endured the consequence of the so-called diagnostic odyssey, i.e., a period that 
encompasses from the initial disease recognition or symptom onset to the date of a 
definitive diagnosis, involving a battery of tests and multiple clinical visits and/or 
referrals, sometimes for several years, all with the hope of identifying the etiology 
of their disease. For more than twenty-five percent of rare disease patients, on an 
average it takes five years before they could be assigned a definite genetic diagnosis. 
Besides, some people will remain undiagnosed for their entire life.
The methodology of genetic testing of rare diseases depends critically on the 
exactness of the following three questions, considering β-thalassemia as an exam-
ple: (1) whether the patient harbors the specific disease causing variant in the specific 
gene, for instance, in the case of β-thalassemia, 80% of all mutations in Greek 
Cypriots are c.93-21G>A; or (2) whether the patient harbors any variant in the 
β-thalassemia gene; or (3) whether the patient harbors any variant in any gene that 
would be responsible for his or her medical condition. Each of the above three ques-
tions can be addressed by employing methods that can detect: (1) specific sequence 
changes in the candidate gene; or (2) sequencing each exon of the candidate gene, 
probably by Sanger sequencing; or (3) by using next generation sequencing (mas-
sively parallel sequencing) technology, respectively.
With the advent of next generation sequencing platforms, such as the massively 
parallel/deep sequencing, has opened up the possibility of rapid identification of 
the disease-causing genes and genes alterations that are responsible for numerous 
rare diseases previously characterized only by clinical description [3]. This new 
technology can be harnessed in several ways for clinical molecular diagnostics 
purposes with its own advantages and disadvantages, for instance, one can sequence 
a panel of candidate genes or whole exome using exome capture kits or whole 
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genome. The major advantage of the whole genome diagnostic sequencing com-
pared with whole exome diagnostic sequencing is that it avoids exon capture, and 
this would allow changes outside coding exons to be identified routinely.
However, over the last decade, research and clinical exome sequencing efforts have 
been successfully harnessed at identifying not only known but missed diagnoses but 
also novel and newly characterized rare genetic syndromes [4, 5]. The utility of clinical 
exome sequencing resulted, with a diagnostic yield in the range of twenty-five to thirty 
percent among large and heterogeneous rare diseases cohorts [6]. Nevertheless, in more 
than seventy percent of patients in whom there was high degree of pre-test probability 
for a monogenic rare disease, exome sequencing renders no molecular diagnosis.
Despite the remarkable capability of exome sequencing to provide molecular diag-
noses for rare disease patients, some pathogenic genomic variants are entirely missed 
by exome sequencing, for example, small insertions-deletions (indels), chromosomal 
rearrangements, and copy-number variants (CNVs), but these causative variants can 
be conclusively diagnosed by short-read genome sequencing. Similarly, rare disease 
secondary to pathogenic repeat expansions or rearrangements can potentially be 
identified or enhanced by long-read genomic sequencing. In addition, some disease 
mechanisms are either difficult or impossible to detect using whole exome sequencing 
approach, for instance, mosaicism of a pathogenic variant may not be routinely dis-
covered by existing analytical approaches, which requires deep sequencing of multiple 
tissues. Even though whole genome sequencing outperforms exome sequencing, 
several other emerging technologies, such as transcriptome sequencing (to evaluate 
the functional consequence of variants) and methylation arrays (to provide insights 
into imprinting disorders), offer added value as adjunct diagnostic tools [7].
In general, several clinical investigations have the potential to reveal findings that 
are not related to the primary reason for the investigation, but that may be clinically 
significant. Evidently, when a patient’s whole exome or whole genome sequencing is 
performed, it has exceptionally high potential to discover clinically relevant inciden-
tal findings. Arguably, the additional concern surrounding the whole exome and/or 
whole genome sequencing is how to handle the incidental findings, as they become 
ever more routine. In this context, the European Society of Human Genetics recom-
mends a much more conservative approach, i.e., whenever possible, testing should 
be targeted to genome regions linked to the patient’s indications [8–10].
Finally, the advancement of genetic medicine and precision medicine can end one 
odyssey and start another one, i.e., for rare disease patients, a genetic result can mark not 
only the end of a ‘diagnostic odyssey’ but also mark the beginning of a ‘therapeutic odyssey.’
3. Conclusions
Rare diseases, even though individually rare, are collective common. Many rare 
conditions are not only chronically debilitating and progressive but also degenera-
tive and life-threatening. Most do not have appropriate treatments, rendering them 
incurable. Consequently, drug, biologic, and device development in the case of rare 
disease is challenging for many reasons, including the complex biology and the lack 
of critical understanding of the nature course of many rare diseases. In addition, the 
inherently fewer population of patients with a rare disease may also cause conduct-
ing clinical trials challenging. Scientists and clinicians around the globe are working 
to find better ways to prevent, detect, and treat rare diseases, and to improve the 
quality of life of patients and their families.
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